secwatch.observer — SEC 8-K summary
======================================

Issuer:     Aclaris Therapeutics, Inc. (ACRS)
CIK:        0001557746
Form:       8-K
Filed at:   2024-02-05T23:59:59+00:00
Accession:  0001558370-24-000769
Event type: leadership
Sentiment:  negative
Materiality: 0.60
Item codes: 5.02
LLM model:  deepseek-v4-flash:cloud@v2

Aclaris terminates CMO, enters separation with former CEO; promotes CSO to full-time
--------------------------------------------------------------------------------

- Terminated Gail Cawkwell as CMO effective Jan 31, 2024, without cause; receives 12-month salary continuation and COBRA coverage.
- Entered separation agreement with former CEO Douglas Manion on Feb 4, 2024; receives 12-month salary continuation plus unpaid 2023 bonus.
- Amended CSO Joseph Monahan's employment; base salary raised to $430,000, moves from part-time to full-time effective Feb 1, 2024.
- Monahan’s new agreement has a 2-year initial term with automatic one-year renewals unless 90-day notice is given.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1557746/000155837024000769/0001558370-24-000769-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1557746/000155837024000769/acrs-20240131x8k.htm
  HTML page:      https://secwatch.observer/filing/0001558370-24-000769

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer